… Key Message: In a relatively treatmentrefractory cohort of inflammatory bowel disease … after
week 30 of vedolizumab therapy. In this study, response to vedolizumab therapy is defined as …

… vedolizumab for active inflammatory bowel disease in a large German cohort over 1 year.
Although the efficacy of vedolizumab … its efficiency as an induction therapy up to week 14,20-23 …

… exist for vedolizumab in inflammatory bowel disease, but results are not as straightforward
as they are for anti-tumour necrosis factor-α therapy. Robust target vedolizumab trough levels …

… to April 2020 to identify studies examining vedolizumab and EIM. We also searched the …
and treatment. We focus on the available data regarding the effectiveness of vedolizumab in …

… in a phase 3 trial in ulcerative colitis and a phase 2 trial in Crohn’s disease. There are 2
other S1P1 modulators in development for patients with inflammatory bowel disease: APD334 (…

… vedolizumab was 9 months (IQR: 7-16). There was no overall change in serum alkaline
phosphatase level with vedolizumab therapy (… % of Crohn's disease and 29% of ulcerative colitis …

… performed to determine the effect of vedolizumab therapy in patients with UC based on …
vedolizumab demonstrated significantly greater efficacy as induction and maintenance therapy …

… vedolizumab for treatment of Crohn’s disease (CD) or … vedolizumab therapy developing
serious adverse events or infections when stratified by concomitant immunosuppressive therapy. …

… Nonetheless, the effect of vedolizumab on … with vedolizumab and promptly developed new
onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy …

… The role of therapeutic drug monitoring with vedolizumab is … of vedolizumab in inflammatory
bowel disease and how drug levels… Vedolizumab clearance is increased with very high body …